AR018252A1 - Forma de dosificacion farmaceutica en particulas solidas adecuada para suministro oral. - Google Patents

Forma de dosificacion farmaceutica en particulas solidas adecuada para suministro oral.

Info

Publication number
AR018252A1
AR018252A1 ARP980104098A ARP980104098A AR018252A1 AR 018252 A1 AR018252 A1 AR 018252A1 AR P980104098 A ARP980104098 A AR P980104098A AR P980104098 A ARP980104098 A AR P980104098A AR 018252 A1 AR018252 A1 AR 018252A1
Authority
AR
Argentina
Prior art keywords
dosage form
solid particles
pharmaceutical dosage
particles suitable
oral supply
Prior art date
Application number
ARP980104098A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR018252A1 publication Critical patent/AR018252A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Dispersiones de partículas solidas de agentes farmacéuticos en una matriz de un polímero soluble en agua que exhiben buena disolucion acuosay aumento de biodisponibilidad.
ARP980104098A 1997-08-21 1998-08-19 Forma de dosificacion farmaceutica en particulas solidas adecuada para suministro oral. AR018252A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5619597P 1997-08-21 1997-08-21

Publications (1)

Publication Number Publication Date
AR018252A1 true AR018252A1 (es) 2001-11-14

Family

ID=22002810

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980104098A AR018252A1 (es) 1997-08-21 1998-08-19 Forma de dosificacion farmaceutica en particulas solidas adecuada para suministro oral.

Country Status (17)

Country Link
US (1) US20010048946A1 (es)
EP (1) EP1011640A1 (es)
JP (1) JP2001515029A (es)
KR (1) KR20010023085A (es)
AR (1) AR018252A1 (es)
AU (1) AU8600098A (es)
BR (1) BR9811972A (es)
CA (1) CA2292586C (es)
CO (1) CO4960652A1 (es)
GT (1) GT199800136A (es)
HN (1) HN1998000115A (es)
NZ (1) NZ502869A (es)
PA (1) PA8458101A1 (es)
PE (1) PE109599A1 (es)
SV (1) SV1998000104A (es)
WO (1) WO1999008660A1 (es)
ZA (1) ZA987551B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1537292A (en) * 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
KR100226553B1 (ko) * 1991-08-02 1999-10-15 윌컴 터프팅 피티와이. 리미티드 터프트 방법 및 장치
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
DZ3227A1 (fr) 1999-12-23 2001-07-05 Pfizer Prod Inc Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
DE60143704D1 (de) * 2000-09-25 2011-02-03 Nippon Shinyaku Co Ltd Verfahren zur herstellung einer medizinischen festen dispersion
ATE293439T1 (de) * 2000-12-07 2005-05-15 Warner Lambert Co Verfahren und system zur gleichmä igen arzneistoffabgabe
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
WO2003063833A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
AU2003249474A1 (en) 2002-08-12 2004-02-25 Pfizer Products Inc. Pharmaceutical compositions of semi-ordered drugs and polymers
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US20050100608A1 (en) * 2003-02-21 2005-05-12 Watson Pharmaceuticals, Inc. Testosterone oral dosage formulations and associated methods
US8273371B2 (en) * 2003-06-27 2012-09-25 Johan Adriaan Martens Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs
GB0315012D0 (en) * 2003-06-27 2003-07-30 Leuven K U Res & Dev Zeotiles
JP2006528181A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 酸分泌を阻害するために有用な薬学的製剤ならびにそれらを作製および使用する方法
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
MXPA06001417A (es) 2003-08-04 2006-05-15 Pfizer Prod Inc Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP2007513145A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 医薬用多微粒子の製造方法
JP2007522217A (ja) * 2004-02-10 2007-08-09 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2598204C (en) 2004-11-09 2015-01-13 Board Of Regents, The University Of Texas System Stabilized hme composition with small drug particles
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
FR2880274B1 (fr) * 2004-12-30 2007-04-13 Pierre Fabre Medicament Sa Dispersion solide stable d'un derive d'alcaloides de vinca et son procede de fabrication
US20060147518A1 (en) * 2004-12-30 2006-07-06 Pierre Fabre Medicament Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
US9061015B2 (en) * 2004-12-30 2015-06-23 Pierre Fabre Medicament Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
BRPI0608609A2 (pt) * 2005-05-10 2010-01-19 Novartis Ag processo de extrusço para preparaÇço de composiÇÕes com compostos terapÊuticos fracamente compressÍveis
GB0612695D0 (en) * 2006-06-27 2006-08-09 Univ Gent Process for preparing a solid dosage form
WO2008074097A1 (en) * 2006-12-21 2008-06-26 Alphapharm Pty Ltd Pharmaceutical compound and composition
MX2010014566A (es) * 2008-07-03 2011-02-15 Novartis Ag Proceso de granulacion de fundido.
WO2010136604A1 (en) * 2009-05-29 2010-12-02 Dsm Ip Assets B.V. Transfer matrix for transferring a bioactive agent to body tissue
EP2675434A1 (en) 2011-02-17 2013-12-25 F.Hoffmann-La Roche Ag A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion
EP2765993B1 (en) * 2011-09-14 2020-05-20 Amgen (Europe) GmbH Formulations of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2, 3-dihydro-1h-isoindol-4-yl}-amide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
JPH054919A (ja) * 1990-07-25 1993-01-14 Sankyo Co Ltd チアゾリジン誘導体の固体分散体
AU1537292A (en) * 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
DK0617612T3 (da) * 1991-12-18 1998-04-14 Warner Lambert Co Fremgangsmåde til fremstilling af en fast dispersion
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
DE4226753A1 (de) * 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
JPH07324086A (ja) * 1994-05-31 1995-12-12 Sankyo Co Ltd チアゾリジン誘導体の固体分散体または固体分散体製剤
DE19515972A1 (de) * 1995-05-02 1996-11-07 Bayer Ag Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
CA2292586A1 (en) 1999-02-25
GT199800136A (es) 2000-02-11
HN1998000115A (es) 1999-06-02
PA8458101A1 (es) 2001-12-14
WO1999008660A1 (en) 1999-02-25
ZA987551B (en) 1999-02-23
SV1998000104A (es) 1999-07-02
EP1011640A1 (en) 2000-06-28
CO4960652A1 (es) 2000-09-25
AU8600098A (en) 1999-03-08
PE109599A1 (es) 1999-12-19
CA2292586C (en) 2006-02-14
JP2001515029A (ja) 2001-09-18
US20010048946A1 (en) 2001-12-06
NZ502869A (en) 2002-10-25
BR9811972A (pt) 2000-08-15
KR20010023085A (ko) 2001-03-26

Similar Documents

Publication Publication Date Title
PA8458101A1 (es) Formas de dosificacion farmaceuticas solidas
CR7661A (es) Composicion de comprimido de liberacion sostenida de pramipexol
JP2001515029A5 (es)
CO5611097A2 (es) Tableta farmaceutica
WO2002045684A3 (en) Rapidly dispersing pharmaceutical composition comprising effervescent agents
MX9300998A (es) Sistema mejorado de liberacion farmaceutica y metodo para su preparacion.
ATE253894T1 (de) Pharmazeutische suspensionssysteme
PT1183014E (pt) Composicoes farmaceuticas orais de libertacao controlada e de dissimulacao de sabor
ATE333265T1 (de) Oral anzuwendende schnell zerfallende feste darreichungsformen
MY135852A (en) Pharmaceutical products
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
AR030862A1 (es) Formulaciones medicinales en aerosol
UY24888A1 (es) Tabletas de oxacarbazepina recubiertas de pelicula
MX9700082A (es) Composicion que consiste de morfina, polipirrolidona y oxido de polialquileno.
AR002947A1 (es) Composicion para la liberacion controlada de un estimulante de xantina o de un derivado de xantina y metodo para preparar dicha composicion
EP2298285A3 (en) Method of making particles for use in a pharmaceutical composition
ZA997727B (en) Pharmaceutical composition for application to mucosa.
BG105257A (en) New oral formulation for 5-ht4 agonists or antagonists
DE60038536D1 (de) Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe
DE60314265D1 (de) Pharmazeutische zusammensetzungen mit modafinil
HRP20010684B1 (hr) Izravno stlaciva matrica za kontrolirano otpustanje jednostruke dnevne doze klaritromicina
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
UY26861A1 (es) Composición de eletriptan en forma de partículas
CA2317954A1 (fr) Dispositif d'enrobage pour granules a absorber par voie orale
PA8468001A1 (es) Aparato para inhalar medicamentos en estado de polvo

Legal Events

Date Code Title Description
FB Suspension of granting procedure